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SummAry Cathepsins are lysosomal cysteine proteases, which 
are involved in a variety of physiologic processes such as proen-
zyme activation, antigen presentation, tissue remodeling, bone 
matrix resorption, and pathologic processes such as facilitating 
tumor invasion and modulating the process of programmed cell 
death. This study aimed to evaluate the pattern of cathepsin D 
(CD) expression in chronic plaque psoriasis in comparison to nor-
mal skin by means of immunohistochemistry. The study included 
34 patients presenting with chronic plaque psoriasis and 10 age- 
and sex-matched normal subjects as control group. Sixty per-
cent of normal skin showed granular positivity for CD confined 
to basal layer. CD is upregulated in psoaritic lesion with 94.1% 
positivity making a significant difference between psoriasis and 
normal skin as regards the percentage and distribution of CD ex-
pression, where the latter was predominantly diffuse in psoriatic 
lesion. The eight cases exposed to PUVA therapy showed reduc-
tion of CD positivity to 62.5% with a predominance of mild stain-
ing and focal expression compared to pretreatment biopsies. CD 
may have a role in the pathogenesis of psoriasis in view of its 
high percentage and diffuse expression in psoriatic epidermis. 
CD degradative capacity may be responsible for disordered dif-
ferentiation and scale formation characteristic of psoriasis. Re-
duction of CD expression may be one of the pathways of PUVA 
mechanism of action.
KEy worDS: psoriasis, cathepsin D, proteases, immunohisto-
chemistry
IntroDuCtIon 
Psoriasis is a common, chronic, disfiguring, in-
flammatory and proliferative condition of the skin, 
in which both genetic and environmental influences 
have critical roles (1). It is currently thought to be a T 
cell mediated type I autoimmune disease (2).
Proteases are essential for cell and tissue homeo-
stasis. Cathepsins, which are lysosomal cysteine prote-
ases, are involved in a variety of physiologic processes 
such as proenzyme activation, antigen presentation, 
hormone maturation, tissue remodeling, and bone 
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matrix resorption (3). Cathepsins also act as media-
tors of programmed cell death (4). Their implication 
in numerous vital processes and pathologies make 
them highly attractive targets for drug design (5).
Cathepsin D (CD) is a major intracellular aspartic 
protease of endosomes and lysosomes and is related 
to other aspartic proteases such as renin, pepsin and 
yeast protease A. All these enzymes are synthesized 
as inactive precursors, which are then processed ei-
ther autocatalytically (e.g., pepsin) (6) or by other 
enzymes (e.g., renin) to remove an N-terminal pro-
peptide (7). CD is involved in the proteolytic activa-
tion as well as proteolytic degradation of intracellular 
proteins (8). Increased levels of  CD are correlated with 
tumor cell invasion and metastasis in malignant mel-
anoma, squamous cell carcinoma and human breast 
cancer (9).
In skin, CD plays a role in both extracellular and 
intracellular catabolism. It may be involved in the 
control of cell differentiation during normal develop-
ment and is thought to be associated with the final 
stage of desquamation (10).
The aim of this study was to evaluate the pattern 
of CD expression in chronic plaque psoriasis in com-




The study was carried out in 34 patients present-
ing with chronic plaque psoriasis. The diagnosis was 
made on clinical and histopathological basis and all 
patients had received neither topical nor systemic 
treatment for at least 2 weeks before skin biopsy. 
Eight cases were followed after receiving PUVA ther-
apy, where biopsies were taken post treatment and 
immunohistochemically stained for CD.
Control group
Ten age- and sex-matched apparently healthy 
volunteers were included in the study as a control 
group.
Both patients and control subjects were selected 
randomly from the Outpatient Dermatology Clinic, 
Menoufiya University Hospital during the period be-
tween July 2008 and June 2009.
The studied cases underwent complete history 
taking; general and dermatologic examinations; and 
skin biopsies. Biopsy samples were obtained under 
local anesthesia from all cases (lesions) and controls 
after obtaining a written consent. All biopsies were 
processed at Pathology Department, Faculty of Medi-
cine, Menofiya University, where they were fixed in 
10% neutral buffered formalin, dehydrated in ascend-
ing grades of ethanol followed by immersion in xy-
lene, then impregnated in paraffin. Several 5-micron 
(5-μm) thick sections from each block were taken: 
one to be stained with hematoxylin & eosin (H&E) for 
routine histopathological examination, while other 
sections were mounted on Super frost Plus slides and 
stored at room temperature, one to be stained im-
munohistochemically for CD and another one served 
as a negative control. Breast carcinoma tissue was 
used as a positive control. The primary antibody was 
mouse monoclonal antibody (cat.#MS-402-S0) raised 
against CD (Labvision, USA). It is received as 0.1 mL 
conc. and diluted by phosphate buffer saline (PBS) 
at 1:50 dilution. The sections underwent subsequent 
steps of deparaffinization, rehydration and boiling 
in citrate buffer solution (pH 6) for 20 minutes, fol-
lowed by cooling. Incubation with primary antibody 
was done overnight at room temperature. Incubation 
with secondary antibody and product visualization 
was performed employing Envision (Dako Cytoma-
tion, Glostrup, Denmark) method with diaminoben-
zidine (DAB) substrate chromogen. Slides were finally 
counterstained with Mayer’s hematoxylin.
Immunostained sections for CD were  
assessed as follows:
Cathepsin D immunoreactivity was evaluated as 
negative or positive; granular cytoplasmic expression 
in any number of cells was a prerequisite to assign 
CD positivity. The intensity of CD expression was as-
sessed subjectively as mild, moderate and strong. The 
extent of CD expression was evaluated as diffuse or 
focal; diffuse expression indicated CD staining of all 
epidermal layers, while focal expression was assigned 
if not all epidermal layers stained for CD. 
Statistical analysis 
Results were collected, tabulated, statistically ana-
lyzed on IBM personal computer using SPSS version 
11 statistical package. Fisher exact test was used to 
study association between two qualitative variables. 
Mann-Whitney test (nonparametric test) was used for 
comparison between two groups not normally dis-
tributed having quantitative variables. A P-value of 
<0.05 was considered statistically significant.
rESultS
Clinical and histopathologic features of examined 
psoriatic cases are presented in Table 1.
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(20.6%) cases. The intensity of CD expression varied 
among cases and showed mild, moderate and strong 
expression.  Mild intensity was seen in 11/34 (32.4%), 
moderate in 15∕34 (44.1%) (Fig. 3) and strong in 6/34 
(17.6%) cases (Fig. 2). Only two cases 2/34 (5.9%) 
showed complete absence of CD expression.
Comparison of CD expression between 
control and psoriatic cases
There was a significant difference between control 
and psoriatic cases regarding CD expression, since 
6/10 (60%) of control cases showed CD expression 
in comparison to high positive expression in 32/34 
(94.1%) psoriatic cases.
As regards CD distribution, there was a highly 
significant difference between control and psoriatic 
cases, since all positive control cases had focal CD 
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CD status in normal skin (control cases)
Granular staining pattern characteristic of CD was 
seen in 6/10 (60%) cases, which was focally expressed 
mainly in the basal layer of the epidermis (Fig. 1), 
while the remaining four cases were completely neg-
ative for CD. The intensity of staining ranged between 
mild degree in four cases to moderate in two cases. 
CD status in chronic plaque psoriasis
Cathepsin D was expressed in 32/34 (94.1%) cases 
as cytoplasmic granules, with diffuse (Fig. 2) expres-
sion in 25/34 (73.5%) and focal staining (Fig. 3) in 7/34 
Figure 1. Cathepsin D expression in the basal layer of nor-
mal skin (immunohistochemical staining, X400).
Figure 2. Strong diffuse granular expression of cathepsin D 
in psoriatic lesion (immunohistochemical staining; (A) X200 
and (B) X400).
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expression localized mainly to basal epidermal layer, 
whereas most (73.5%) of psoriatic cases had diffuse 
distribution (Table 2).
Cathepsin D expression and clinicopatho-
logic parameters in psoriatic group
CD positivity as well as intensity and distribution 
of expression did not differ statistically as regards the 
studied clinical and pathologic parameters (data not 
shown).
Eight cases were followed after receiving PUVA 
therapy where biopsies were obtained post-treatment 
and immunohistochemically stained for CD revealing 
reduction in the positivity to reach 62.5%. Positive cas-
es showed mild staining in most cases (4/5) and only 
one case showed moderate staining. All positive cases 
showed focal expression, which was significantly dif-
ferent from CD distribution in specimens before treat-
ment, since 75% of pretreatment biopsies showed dif-
fuse expression (Table 3, Fig. 4). 
DISCuSSIon
The epidermis is a multilayered squamous epithe-
lium composed mainly of keratinocytes that migrate 
from the basal layer to the skin surface. During migra-
tion, they undergo epidermal differentiation, i.e. ke-
ratinocytes are transformed into corneocytes. These 
cornified cells form the uppermost layer of the skin, 
the stratum corneum, which provides a protective 
barrier between our body and the environment. Cor-
neocytes are eventually eliminated by a process called 
desquamation. Proteases are important players in the 
process of keratinocyte differentiation, particularly 
during the desquamation process. Desquamation re-
quires degradation of corneodesmosomes, modified 
desmosomal structures that account for the adhesion 
of corneocytes in the stratum corneum (11).  Desmo-
somes comprise the junctions holding together the 
outer squames of the stratum corneum. Desmoglein 
1 is a component of the desmosomal protein complex 
whose postulated roles in late differentiation include 
squame adhesion. Desmoglein 1 must be cleaved in 
order to attain final squame separation; because the 
stratum corneum is a nonviable tissue, it can only be 
achieved by enzymatic degradation (12).
Figure 3. Moderate diffuse (A) and focal (B) expression 
of cathepsin D in psoriatic lesion (immunohistochemical 
staining, X200).
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table 2. Comparison of cathepsin D expression between 
psoriatic cases and control group


















































NS = nonsignificant; S = significant; HS = highly significant 
table 3. Evaluation of treatment effect (PUVA) on CD im-
munostaining in eight psoriatic cases

















































NS = nonsignificant, S = significant
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In our study, CD was expressed in the basal lay-
er of normal epidermis of control cases, which may 
suggest its role in the degradation system of newly 
generated epidermal cells similar to the basal expres-
sion of cathepsin B and D in rat skin (8). In addition, 
according to Lazarus and Poole (13), CD is immuno-
localized to the basal layer of rabbit epidermis and 
its detection was moderate to weak in lower spinous 
and basal layer of the skin. It has been shown bio-
chemically that CD is present in the stratum corneum 
of normal skin and participates in its desquamation 
(10,14). Demonstration of CD expression in normal 
epidermis may assume its role in degradation of un-
needed proteins resulting from drastic structural 
alterations in epidermal cells. Cathepsin D was dem-
onstrated to be crucially involved in the activation of 
TGase 1 and in the regulation of cornified cell envelop 
(CE) protein expression during epidermal differentia-
tion (15). CD-deficient mice revealed reduced TGase 1 
activity and reduced protein levels of the CE proteins 
involucrin and loricrin. It is suggested that epidermal 
hyperkeratosis is the result of a diminished ability of 
corneocytes to bind intercellular lipids, caused by the 
reduced expression of involucrin and loricrin in the 
stratum corneum.
It is suggested that CD may be involved in the 
control of cell differentiation during normal develop-
ment. Horikoshi et al. (14) found increased expression 
and increased activity of CD isoforms in the skin de-
pending on the stage of epidermal differentiation. 
Igarashi et al. (12) found that this aspartic proteinase 
CD with a peak activity at pH 4 may play an essential 
role in the process of desquamation of normal epi-
dermis. They also demonstrated CD to be abundantly 
present in the granular and stratum corneum layers 
(fully activated in the stratum corneum). In viable 
epidermis, it is predominantly confined to lysosomes 
of the spinous and granular layers. Apparently, CD is 
activated in lysosomes of the granular layer, where 
it can participate in the massive degradative pro-
cesses that accompany cornification, including the 
activation of transglutaminase. In the upper granular 
and transition layers of the normal epidermis, CD is 
spewed out into the intercellular spaces between the 
adjacent corneocytes, where it becomes associated 
with desmosomes to function in further degradative 
processes unique to the stratum corneum, the last of 
which is desquamation.
Vashishta et al. (16) demonstrated human kerati-
nocytes to secrete significant amount of procathep-
sin D. The secreted procathepsin D affects the prolif-
eration of HaCaT cells and also induces secretion of 
cytokines that help in normal physiologic functions 
such as overcoming stresses and enhancing the re-
generation process of wound healing as an example 
of keratinocyte growth.
Premature activation of CD in the spinous layer 
would interrupt the orderly process of epidermal 
differentiation. This interruption is confirmed in pso-
riasis, a disease in which the cohesive forces holding 
adjacent squames together are altered, leading to 
premature desquamation. The psoriatic plaque is ab-
normal in that the granular and transitional cell lay-
ers are attenuated. Organelles, including the nuclei, 
are normally degraded in these layers; nuclei are re-
tained in the psoriatic stratum corneum. Involucrin is 
cross-linked by transglutaminase in the granular cells 
into the cornified envelope (17) and has been local-
ized to the upper spinous and granular layers of the 
normal epidermis (18). It is expressed precociously in 
the psoriatic epidermis (18) and this premature ex-
pression has been associated with hyperproliferation 
(19). As CD has been implicated in the activation of 
transglutaminase (20), it may contribute to catalyzing 
enzymatic processes during cornification. The cohe-
sive forces holding together adjacent squames of the 
stratum corneum are altered in psoriasis; this leads to 
premature desquamation. The active forms of CD im-
munolocalize to the transition layer and stratum cor-
neum in normal epidermis, but they do not label the 
stratum corneum of the psoriatic plaque. CD, like in-
volucrin, is precociously expressed in psoriatic cells.
In our study, CD was expressed in 94.1% of psori-
atic lesions and was seen staining the whole epider-
mal layer of the lesions, compared to Kawada et al. 
(9) and Chen et al. (21) who found all psoriatic cases 
to show positive expression. In psoriatic epidermis, it 
has been found that the CD antibody labels all the vi-
able layers but not the stratum corneum (21) and its 
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Figure 4. Post PUVA therapy showing faint basal expression 
of cathepsin D (immunohistochemical staining, X200).
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expression in spinous layer was strong and may be 
responsible for desquamation and scale formation in 
psoriasis depending on its degenerative capacity by 
stimulation of transgltaminase. Granular staining of 
CD seen in our study and in others refers to its lyso-
somal location.
In our study, we found that CD expression in pso-
riatic epidermis was significantly higher compared 
to control group (P<0.05), confirming its role in the 
pathogenesis of chronic plaque psoriasis and consis-
tent with Kawada et al. (9) who found cathepsins L, B 
and D to play a role in the pathogenesis of psoriasis; 
they suggest that CD in psoriasis is mainly activat-
ed and partially proteolysed. Egberts et al. (15) also 
found a significant increase in epidermal expression 
of the active intermediate as well as the mature form 
of CD in psoriasis.
Depending on the environment, CD can induce 
or inhibit apoptosis, acting through different mech-
anisms. Minarowska et al. (22) found CD to play an 
important role in apoptosis, and the mature form of 
CD to regulate intrinsic apoptosis pathway through 
stimulation of cytochrome C (CytC) release from mi-
tochondrion. Berchem et al. (23) observed that 3Y1-
Ad12 cell lines transfected with CD gene showed 
overexpression of CD, which can prevent apoptosis 
independently of the catalytic function of CD. Sup-
pression of apoptosis is one of the pathogenic mech-
anisms of induction of psoriasis (24).
Several authors have suggested that CD is involved 
in the regulation of blood vessel formation, especially 
in solid tumors. Significant association between CD 
expression of host stromal cells and vascular density 
was described in breast cancer tumors (25) and ovar-
ian tumors (26). Angiogenesis is one of the hallmarks 
of the pathogenesis of psoriasis, which could be 
enhanced by the overexpression of CD, since it may 
influence the production and degradation of both 
activators and inhibitors in vitro. Briozzo et al. (26) ob-
served CD to facilitate the release of pro-angiogenic 
bFGF from ECM. Moreover, CD is able to inactivate the 
anti-angiogenic factors including angiostatin, 16K 
prolactin (PRL) and endostatin in vitro (28).
According to Vallat et al. (29), PUVA therapy leads 
to complete reversal of pathological epidermal 
changes and lymphocytic activation, where they 
showed an overall reduction of epidermal acantho-
sis in lesional psoriatic skin by 58%. PUVA treatment 
of lesional psoriatic skin also led to thinning of both 
the stratum Malpighi and stratum corneum, return-
ing of the granular layer, restoration of keratinocyte 
maturation with nuclear elimination (orthokeratotic 
maturation), and elimination of neutrophils from the 
stratum corneum. Our results showed either com-
plete absence of CD expression in the epidermis ex-
posed to PUVA, or just its faint and focal expression in 
the basal layer, which is consistent with Kawada et al. 
(9), who found the cathepsins L, B and D expression 
to have recovered to normal in specimens from pa-
tients after PUVA treatment, which may also support 
the concept of cathepsins involvement in the patho-
genesis of psoriasis. 
ConCluSIon
According to our study results, CD may have a role 
in the pathogenesis of psoriasis in view of its high 
percentage and diffuse expression in psoriatic epi-
dermis. CD degradative capacity may be responsible 
for disordered differentiation and scale formation 
characteristic of psoriasis. Reduction of CD expres-
sion may be one of the pathways of the PUVA mecha-
nism of action.
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